AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER).
Aminosyn II 4.25% w/ Electrolytes in Dextrose 25% is a parenteral nutrition formulation providing amino acids for protein synthesis and dextrose as a carbohydrate calorie source. The amino acids serve as substrates for protein synthesis, while dextrose provides glucose for cellular energy metabolism via glycolysis and the citric acid cycle. Electrolytes are included to maintain acid-base and fluid balance, and to support enzymatic functions and membrane potentials.
| Metabolism | Amino acids are metabolized via transamination, deamination, and the urea cycle in the liver and other tissues; carbon skeletons enter the citric acid cycle or gluconeogenesis. Dextrose undergoes glycolysis and subsequent oxidative metabolism in all tissues; excess glucose may be stored as glycogen or converted to fat. Electrolytes are excreted or reabsorbed according to renal and homeostatic mechanisms. |
| Excretion | Amino acids are metabolized to urea (liver) and CO2; nitrogen is excreted renally as urea (80-90%), with minimal (<5%) biliary/fecal. Dextrose is metabolized to CO2 (exhaled) and water. Electrolytes are excreted renally proportional to intake and homeostasis. |
| Half-life | Not applicable as a single entity; amino acids have rapid turnover (minutes to hours) with no terminal half-life. Dextrose has a half-life of 15-20 minutes under steady-state conditions. |
| Protein binding | Amino acids: minimally bound (<10%) to albumin. Dextrose: not bound. Electrolytes: variable (e.g., calcium ~40% bound to albumin). |
| Volume of Distribution | Not applicable as a combination; amino acids distribute to total body water (approx 0.6 L/kg). Dextrose distributes to extracellular fluid (approx 0.2 L/kg). Electrolytes distribute to specific compartments (e.g., sodium extracellular). |
| Bioavailability | 100% (IV administration). Not applicable for oral route (no oral formulation for this concentration). |
| Onset of Action | Immediate upon IV infusion; amino acids incorporation into protein synthesis begins minutes to hours. Dextrose raises blood glucose within 5-10 minutes. Electrolytes act as infused. |
| Duration of Action | Duration equals infusion time; metabolic effects persist for hours after infusion (e.g., nitrogen retention, blood glucose elevation). Continuous infusion required for sustained effect. |
Intravenous infusion. Adult dose: 500 mL to 1000 mL per 24 hours, adjusted to meet protein and calorie requirements. Typical infusion rate: 1.5-2.0 mL/kg/hour, not exceeding 3.0 mL/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: Use with caution, reduce dose by 50% or use renal-specific amino acid formulations. GFR 30-50 mL/min: Reduce dose by 25%. GFR >50 mL/min: No adjustment necessary. |
| Liver impairment | Child-Pugh Class C: Avoid use due to risk of hepatic encephalopathy. Child-Pugh Class B: Reduce dose by 50% and monitor ammonia levels. Child-Pugh Class A: No specific dose adjustment, but monitor liver function. |
| Pediatric use | Weight-based dosing: 0.15-0.3 g amino acids per kg per day initially, titrate up to 0.5-1.0 g/kg/day as tolerated. Dextrose component provides 0.25 g/mL; adjust rate to avoid hyperglycemia. Typical infusion rate: 2-3 mL/kg/hour in neonates, 1-2 mL/kg/hour in older children. |
| Geriatric use | Start at lower end of adult dosing (500 mL/24 hours), monitor renal function and electrolytes, adjust rate to avoid fluid overload. Use with caution in patients with reduced cardiac or renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER).
| Breastfeeding | Safety during breastfeeding is likely acceptable as components are normal metabolic substrates. Dextrose and amino acids are present in breast milk but infusion adds minimal excess. M/P ratio not available for the combination. Monitor infant for excessive weight gain or feeding issues. |
| Teratogenic Risk | Aminosyn II 4.25% with Electrolytes in Dextrose 25% is a parenteral nutrition solution. Dextrose at high concentrations may cause fetal hyperglycemia and hyperinsulinemia if maternal glucose levels are elevated. No specific teratogenic effects are documented for amino acids or electrolytes at therapeutic doses. During the first trimester, avoid maternal hyperglycemia. In second and third trimesters, monitor maternal glucose and adjust dextrose infusion to prevent fetal hyperinsulinemia and neonatal hypoglycemia. |
■ FDA Black Box Warning
None
| Serious Effects |
["Absolute: Hypersensitivity to any component (amino acids, dextrose, electrolytes).","Severe hyperglycemia or uncontrolled diabetes mellitus.","Severe electrolyte imbalance (e.g., severe hyperkalemia, hyperphosphatemia) that cannot be corrected.","Anuria or severe renal impairment without appropriate electrolyte adjustment.","Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria) unless specialized formulation is used.","Metabolic acidosis not corrected."]
| Precautions | ["Risk of hyperglycemia, hyperosmolar syndrome, and rebound hypoglycemia upon abrupt discontinuation. Monitor blood glucose closely.","Risk of fluid and electrolyte imbalances, including hyperkalemia, hyperphosphatemia, and metabolic acidosis. Adjust electrolytes based on patient status.","Risk of central line-associated bloodstream infection (CLABSI) and catheter-related complications with IV administration.","Hepatic steatosis and cholestasis in long-term use, especially with excessive caloric intake.","Aluminum toxicity with prolonged use, particularly in renal impairment.","Monitoring of serum osmolarity, acid-base status, liver function, and renal function is required."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, glucose, blood urea nitrogen, creatinine, liver enzymes, triglycerides, and osmolarity. Fetal monitoring includes growth ultrasound and non-stress test if dextrose administration causes hyperglycemia. Check neonatal glucose after delivery. |
| Fertility Effects | No adverse effects on fertility reported. Nutritional support may improve fertility in malnourished patients. |
| Food/Dietary |
| No oral food interactions as this is intravenous therapy. However, concurrent oral intake may alter nutritional balance; monitor for refeeding syndrome in malnourished patients. |
| Clinical Pearls | This is a high-osmolality parenteral nutrition solution (approx. 1700 mOsm/L) requiring central venous administration. Monitor serum electrolytes, glucose, triglycerides, and liver function tests closely. Avoid abrupt discontinuation to prevent rebound hypoglycemia. Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders. |
| Patient Advice | This nutrition is given through a central vein and requires careful monitoring. · Report any signs of infection (redness, swelling, pain) at the catheter site. · Inform your healthcare provider if you experience nausea, vomiting, or abdominal pain. · Do not stop this infusion suddenly without medical advice. · Regular blood tests are needed to check blood sugar, electrolyte levels, and liver function. |